🇺🇸 FDA
Patent

US 10100312

Compositions and methods for inhibiting expression of TMPRSS6 gene

granted A61KA61K31/713A61P

Quick answer

US patent 10100312 (Compositions and methods for inhibiting expression of TMPRSS6 gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/713, A61P, A61P3/00, A61P3/12